{"id":740797,"date":"2023-03-16T13:13:04","date_gmt":"2023-03-16T17:13:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/"},"modified":"2023-03-16T13:13:04","modified_gmt":"2023-03-16T17:13:04","slug":"biondvax-to-present-at-bio-europe-spring","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/","title":{"rendered":"BiondVax to Present at BIO-Europe Spring"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">JERUSALEM, March  16, 2023  (GLOBE NEWSWIRE) &#8212; via InvestorWire\u00a0<strong>\u2013 <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T2WC0xLuV56zMN9vjCmDRdUZxWa0BiwkmS7eGPSYxtO66jPD4tvUQBsN9gMqzaN_IQGkUlwPFqMXs2M6pmzRjLAgzd-_OVtj8eo8tWfa6Ns=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>BiondVax Pharmaceuticals Ltd<\/u><\/strong><\/a><strong>.<\/strong> (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GWOwkjDIyZs8aOo3t_mRkGkPUMbBQxNxUkXF71ZJyndm4u1maOWK-kPkQiWhssOtytx56eXocyov4FcaQluPukwz8irSkSuVDTlqubCFIk2Jt1MX_YHjhZLBScJ-Jwqy\" rel=\"nofollow noopener\" target=\"_blank\"><u>Amir Reichman<\/u><\/a> will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20\u201322, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<ul>\n<li>Date: Tuesday, March 21, 2023<\/li>\n<li>Time: 11:30 a.m.<\/li>\n<li>Location: Messe Basel, North Entrance, Exhibit Hall Stage<\/li>\n<\/ul>\n<p align=\"justify\">Reichman\u2019s presentation will focus on recent <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3vtkEBQaq4_Z0R9cEbzBrgbOqrjPElDF1rzuuOzrPr1wZLcfm-KVIxNTm06AMkqinps8v6cIu6GqLDZbWngyqAtCQNjQ4T92Q3OJHtmvSryRCBqNZcfRxc6_alP953qFpndcBJl2lputIoWhu52rjo74pEEKUnE5_pYHuJES_ZLkhQtKI-tJnon-fDul9c0BQBbf2XhlGlsKtGsIF-hJcyx_nlKLuX5mELlKENwri8DwcugY2e_CjNSXFcp4rayqXq0LgDjKZBCfqxZ1qt5zEOX0tLCum1PqgeAokhiBZXnmeAtGtgqMdSfSo7j2VgQmk-A0tomVLoX-O5bihMbF5qvpzpY5EjG-AbSg2Xbwnu8tpi3qESWu8gGf3U5bMrpz2K6UMZI1GdRhS7cVkWGgmQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>successful preclinical in vivo results of BiondVax\u2019s innovative inhaled COVID-19 treatment<\/u><\/a> and additional pipeline plans, including nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration. BiondVax\u2019s de-risked R&amp;D strategy includes generating a pipeline of bio-better NanoAbs aimed at molecular targets validated by currently approved monoclonal antibodies (mAbs) addressing diseases with underserved medical needs and attractive commercial opportunities.<\/p>\n<p align=\"justify\">Reichman and Joshua Phillipson, Director of Investor Relations and Communications, will be available to meet potential partners, collaborators, and investors. To schedule a meeting with BiondVax register now at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8WWpJA04RSd22e-ixD8t7XB02Br9Yt5OkFn4hrxrMhuWUYt1tAQHFsZIu25VgnYXvE8weInAi5zr1Y3h0LdAeWwALqNujcEzz6pwbiJFAv3lXb6O9RruiWrwKv8zmBfSgl3ffsC8lxbm8NOzoCHk-A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/informaconnect.com\/bioeurope-spring\/<\/u><\/a>. Alternatively, reach out to the Company directly at the contact information below.<\/p>\n<p align=\"justify\">\n        <strong>About BiondVax<\/strong><br \/>\n        <br \/>BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aqJypbcM5EpGFi8qcJjUSSbJJDZ9bTNKTYEGZgtBikIEA0jF969VwHPYan8iY-YR85cf5GINj2dXEfAftbBPSw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.biondvax.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Contact Details<\/strong><br \/>\n        <br \/>Joshua E Phillipson | +972 8 930 2529 | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iuh_lme1gVuij7Is2tJQODcukO6NwSmja_VWnzptUGjqUiO7CJfI2Oh9I6PnzL0WO7K7bt6f_w0TOMoKojxni1LY9bkzf3phhLkuE_JNkaw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>j.phillipson@biondvax.com<\/u><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as \u201cexpect,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201canticipate,\u201d and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financings, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, acquiring an additional license from Max Planck for the therapeutic and commercial potential of nanosized antibodies (NanoAbs); and the timing of NanoAb proof-of-concept studies and clinical trials and the necessary steps needed for such studies and trials. These forward-looking statements reflect management\u2019s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that we may not obtain a second NanoAb license from Max Planck for a NanoAb targeting IL-17 as a treatment for psoriasis, the risk of a delay in proof-of-concept studies and the commencement of clinical trials for NanoAbs, if any, and delays in the necessary steps needed for such studies and trials; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk that clinical trials relating to NanoAbs will fail in whole or in part; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax\u2019s ability to acquire rights to additional product opportunities; BiondVax\u2019s ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax\u2019s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading \u201cRisk Factors\u201d in the Company&#8217;s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.<\/em>\n      <\/p>\n<p>\n        <strong>Corporate Communications:<\/strong><br \/>\n        <br \/> InvestorBrandNetwork (IBN)<br \/> Los Angeles, California<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NnGsE0vdQ-JiYxC6aZhX2xKpUvwL5KFko_ptCnXVwl031kIBhCZ-cczVs7uyHygseCJFH1KSLZCW7AB1Z6R1xXtOsuZMN-9SZY6Z2a-Zr50uEzJpssGBJ4pHXFt1BBJ4\" rel=\"nofollow noopener\" target=\"_blank\">www.InvestorBrandNetwork.com<\/a><br \/> 310.299.1717 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SQ4U892WsCMko-ujCN2R7D5drM_zutBH-dthBuiidxfBOJcxKxDE7OtUyqAs2cCCRiChx5tRClqKZvJJPotdmqFf12qo6Fsj1tlA7AEh2G6-CtJ2olmCzkfSfC5Y9rjg\" rel=\"nofollow noopener\" target=\"_blank\">Editor@InvestorBrandNetwork.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODk3Y2E4ZDQtM2Y3NS00ODRkLWFkZjgtZDI0MmIyYjAzMWJiLTUwMDExMTEwMA==\/tiny\/BiondVax-Pharmaceuticals-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) &#8212; via InvestorWire\u00a0\u2013 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20\u201322, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.\u00a0 Presentation Details: Date: Tuesday, March 21, 2023 Time: 11:30 a.m. Location: Messe Basel, North Entrance, Exhibit Hall Stage Reichman\u2019s presentation will focus on recent successful preclinical in vivo results of BiondVax\u2019s innovative inhaled COVID-19 treatment and additional pipeline &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BiondVax to Present at BIO-Europe Spring&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740797","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BiondVax to Present at BIO-Europe Spring - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BiondVax to Present at BIO-Europe Spring - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) &#8212; via InvestorWire\u00a0\u2013 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20\u201322, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.\u00a0 Presentation Details: Date: Tuesday, March 21, 2023 Time: 11:30 a.m. Location: Messe Basel, North Entrance, Exhibit Hall Stage Reichman\u2019s presentation will focus on recent successful preclinical in vivo results of BiondVax\u2019s innovative inhaled COVID-19 treatment and additional pipeline &hellip; Continue reading &quot;BiondVax to Present at BIO-Europe Spring&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T17:13:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BiondVax to Present at BIO-Europe Spring\",\"datePublished\":\"2023-03-16T17:13:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/\",\"name\":\"BiondVax to Present at BIO-Europe Spring - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\",\"datePublished\":\"2023-03-16T17:13:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biondvax-to-present-at-bio-europe-spring\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BiondVax to Present at BIO-Europe Spring\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BiondVax to Present at BIO-Europe Spring - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/","og_locale":"en_US","og_type":"article","og_title":"BiondVax to Present at BIO-Europe Spring - Market Newsdesk","og_description":"JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) &#8212; via InvestorWire\u00a0\u2013 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20\u201322, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.\u00a0 Presentation Details: Date: Tuesday, March 21, 2023 Time: 11:30 a.m. Location: Messe Basel, North Entrance, Exhibit Hall Stage Reichman\u2019s presentation will focus on recent successful preclinical in vivo results of BiondVax\u2019s innovative inhaled COVID-19 treatment and additional pipeline &hellip; Continue reading \"BiondVax to Present at BIO-Europe Spring\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-16T17:13:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BiondVax to Present at BIO-Europe Spring","datePublished":"2023-03-16T17:13:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/","name":"BiondVax to Present at BIO-Europe Spring - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==","datePublished":"2023-03-16T17:13:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MDA4OSM1NDY2OTMxIzUwMDExMTEwMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biondvax-to-present-at-bio-europe-spring\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BiondVax to Present at BIO-Europe Spring"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740797"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740797\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}